<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548194" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548194/" /><meta name="ncbi_pagename" content="Thiabendazole - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Thiabendazole - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Thiabendazole" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/07/20" /><meta name="citation_pmid" content="31643521" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548194/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Thiabendazole" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/07/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548194/" /><meta name="description" content="Thiabendazole is a broad spectrum anthelmintic agent used predominantly in treatment of intestinal pinworm and strongyloides infection, which recently has been replaced by better tolerated agents. Thiabendazole therapy has been shown to cause clinically apparent cholestatic liver injury which is rare, but can be severe." /><meta name="og:title" content="Thiabendazole" /><meta name="og:type" content="book" /><meta name="og:description" content="Thiabendazole is a broad spectrum anthelmintic agent used predominantly in treatment of intestinal pinworm and strongyloides infection, which recently has been replaced by better tolerated agents. Thiabendazole therapy has been shown to cause clinically apparent cholestatic liver injury which is rare, but can be severe." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548194/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Thiabendazole/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548194/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88C0AD046909C100000000010B004A.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548194_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548194_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Theophylline/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/ThiazideDiuretics/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548194_"><span class="title" itemprop="name">Thiabendazole</span></h1><p class="small">Last Update: <span itemprop="dateModified">July 20, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Thiabendazole.OVERVIEW"><h2 id="_Thiabendazole_OVERVIEW_">OVERVIEW</h2><div id="Thiabendazole.Introduction"><h3>Introduction</h3><p>Thiabendazole is a broad spectrum anthelmintic agent used predominantly in treatment of intestinal pinworm and strongyloides infection, which recently has been replaced by better tolerated agents. Thiabendazole therapy has been shown to cause clinically apparent cholestatic liver injury which is rare, but can be severe.</p></div><div id="Thiabendazole.Background"><h3>Background</h3><p>Thiabendazole (thye" a ben' da zole) is a benzimidazole anthelmintic agent similar in structure and mechanism of action to albendazole and mebendazole. The benzimidazoles act by selective binding to beta-tubulin of parasitic worms, causing their immobilization and death. Thiabendazole was approved in the United States in 1967, but has subsequently been withdrawn because of the availability of other, better tolerated anthelmintic agents, such as ivermectin, albendazole and mebendazole. Thiabendazole is, however, still available in other countries and is used in veterinary medicine in the United States. Thiabendazole is also used as a food preservative and fungicide and trace amounts can be detected in some fruit juices and animal products. Its major medical indication is strongyloidiasis infestation. Thiabendazole was formerly available in chewable tablets of 500 mg under the trade name of Mintezol and as an oral suspension. The typical dose in adults was 1500 mg orally daily for 1 to 3 days. The dose in children is based upon body weight. Thiabendazole therapy is associated with frequent minor but troublesome side effects including dizziness, nausea, diarrhea, gastrointestinal upset, headaches and hair loss. Severe adverse events can include liver disease, keratoconjunctivity sicca, photosensitivity, skin rash and hypersensitivity reactions.</p></div><div id="Thiabendazole.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Thiabendazole therapy is associated with serum aminotransferase elevations in up to 36% of patients, but it is usually given for a brief period only and its effects on serum enzyme levels after single dose administration has not been systematically evaluated. Importantly, thiabendazole therapy has also been associated with clinically apparent liver injury which can be prolonged and severe. The onset of injury is usually within 1 to 2 weeks of finishing a 1 to 5 day course of therapy. The pattern of serum enzyme elevations is typically cholestatic. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.autoantibodies/">Autoantibodies</a> are usually negative and fever, arthralgias and rash are uncommon. Several reported cases have been associated with sicca complex marked by parotid enlargement and tenderness, dry eyes and dry mouth arising before the onset of jaundice. The cholestatic injury can be associated with damage to small bile ducts and with prolonged jaundice and/or pruritus and alkaline phosphatase elevations. Several instances of prolonged cholestasis and chronic vanishing bile duct syndrome and end stage liver disease has been reported even after a single dose of thiabendazole.</p></div><div id="Thiabendazole.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Thiabendazole hepatotoxicity appears to be due to an immunological reaction to the drug, which is directed largely at bile, lacrimal, and salivary gland ducts.</p></div><div id="Thiabendazole.Outcome_and_Management"><h3>Outcome and Management</h3><p>While most reported cases of thiabendazole induced liver injury were self-limited, many were marked by severe and prolonged cholestasis. Several cases of prolonged jaundice with vanishing bile duct syndrome and evolution to cirrhosis leading to liver transplantation have been reported. Patients with acute liver injury attributed to thiabendazole should avoid repeat exposure. It is unknown whether there is cross sensitivity with other benzimidazoles (such as albendazole and mebendazole), but there probably is and switching to another class of anthelmintic agents is appropriate if therapy is still needed.</p><p>Drug Class: <a href="/books/n/livertox/AntihelminthicAgents/">Anthelmintic Agents</a></p></div></div><div id="Thiabendazole.CASE_REPORT"><h2 id="_Thiabendazole_CASE_REPORT_">CASE REPORT</h2><div id="Thiabendazole.Case_1_Cholestatic_hepatit"><h3>Case 1. Cholestatic hepatitis followed by chronic cholestatic syndrome and cirrhosis after short course of thiabendazole.(<a class="bk_pop" href="#Thiabendazole.REF.1">1</a>)</h3><p>A 46 year old woman with suspected trichinosis was treated with thiabendazole (25 mg/kg twice daily for 5 days) and prednisone (40 mg/day). Two weeks later, she noted dryness of the eyes and mouth with low grade fever. Shortly thereafter she developed dark urine and pruritus. She had no history of liver disease or drug allergies and drank little alcohol. On admission, she had prominence of the parotid glands and right upper quadrant tenderness without enlargement of the liver or spleen. She was jaundiced but had no other signs of chronic liver disease. Laboratory values showed a total bilirubin of 16.4 mg/dL with a direct of 11.5 mg/dL (Table). Serum aminotransferase levels were 3 to 20 fold elevated and 5&#x02019; nucleotidase was 5 times elevated. Tests for hepatitis A and B and routine autoantibodies were normal. Ultrasound and CT scans of the abdomen showed no abnormalities and endoscopic retrograde cholangiopancreatography revealed no evidence of biliary obstruction. A liver biopsy showed marked intrahepatic cholestasis and a relative paucity of bile ducts. A salivary gland biopsy showed sialadenitis with prominent destruction of acini and ductules. She remained deeply jaundiced, but reevaluation showed no evidence for other liver disease. Over the next 8 months her symptoms of dry mouth and eyes improved, but she continued to have pruritus and mild jaundice. Two and a half years after exposure to thiabendazole she developed ascites and variceal bleeding. A repeat liver biopsy showed a micronodular cirrhosis with little inflammation and no steatosis. She remained negative for antinuclear (ANA), antimitochondrial (AMA), and antimicrosomal antibodies. Shortly thereafter, she underwent liver transplantation; the explant again showed micronodular cirrhosis.</p><div id="Thiabendazole.Key_Points"><h4>Key Points</h4><div id="Thiabendazole.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548194/table/Thiabendazole.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Thiabendazole.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Thiabendazole.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Thiabendazole.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Thiabendazole (25 mg/kg twice daily for 5 days)</td></tr><tr><th id="hd_b_Thiabendazole.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Thiabendazole.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cholestatic pattern (R=~0.8)</td></tr><tr><th id="hd_b_Thiabendazole.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Thiabendazole.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5+ (ultimately leading to cirrhosis and liver transplantation)</td></tr><tr><th id="hd_b_Thiabendazole.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Thiabendazole.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 weeks</td></tr><tr><th id="hd_b_Thiabendazole.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Thiabendazole.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incomplete</td></tr><tr><th id="hd_b_Thiabendazole.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Thiabendazole.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prednisone 40 mg daily for short period</td></tr></tbody></table></div></div></div><div id="Thiabendazole.Laboratory_Values"><h4>Laboratory Values</h4><div id="Thiabendazole.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548194/table/Thiabendazole.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Thiabendazole.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Thiabendazole.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Thiabendazole.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a><br />(U/L)</th><th id="hd_h_Thiabendazole.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Thiabendazole.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a><br />(mg/dL)</th><th id="hd_h_Thiabendazole.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Thiabendazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Thiabendazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Normal</td><td headers="hd_h_Thiabendazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Normal</td><td headers="hd_h_Thiabendazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Normal</td><td headers="hd_h_Thiabendazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Trichinosis</td></tr><tr><td headers="hd_h_Thiabendazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 weeks</td><td headers="hd_h_Thiabendazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">142</td><td headers="hd_h_Thiabendazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">N/A</td><td headers="hd_h_Thiabendazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16.4</td><td headers="hd_h_Thiabendazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Admission</td></tr><tr><td headers="hd_h_Thiabendazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td><td headers="hd_h_Thiabendazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Thiabendazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Thiabendazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">28.1</td><td headers="hd_h_Thiabendazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Liver biopsy</td></tr><tr><td headers="hd_h_Thiabendazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 weeks</td><td headers="hd_h_Thiabendazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">50</td><td headers="hd_h_Thiabendazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">248</td><td headers="hd_h_Thiabendazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">23.5</td><td headers="hd_h_Thiabendazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AMA and ANA negative</td></tr><tr><td headers="hd_h_Thiabendazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 year</td><td headers="hd_h_Thiabendazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">108</td><td headers="hd_h_Thiabendazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">584</td><td headers="hd_h_Thiabendazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.2</td><td headers="hd_h_Thiabendazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sicca syndrome resolved</td></tr><tr><td headers="hd_h_Thiabendazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.5 years</td><td headers="hd_h_Thiabendazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">98</td><td headers="hd_h_Thiabendazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">487</td><td headers="hd_h_Thiabendazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.6</td><td headers="hd_h_Thiabendazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Variceal hemorrhage</td></tr><tr><td headers="hd_h_Thiabendazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Thiabendazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Thiabendazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;98</b></td><td headers="hd_h_Thiabendazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Thiabendazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Thiabendazole.Comment"><h4>Comment</h4><p>Thiabendazole typically causes an acute cholestatic hepatitis, but in half of cases the cholestatic hepatitis has been preceded by onset of a sicca syndrome with dry eyes and dry mouth and parotid enlargement, with salivary gland biopsies showing inflammation and damage to acini and ductules. The cholestatic hepatitis may also be characterized by damage to bile ducts and result in a prolonged jaundice or cholestasis, with persistence of liver test abnormalities for months or years. In its most severe form, this prolonged cholestasis is also marked by vanishing bile duct syndrome and chronic cholestasis that can result in cirrhosis, portal hypertension and end stage liver disease. The condition resembles primary biliary cirrhosis, but typically presents in an acute fashion with jaundice and symptoms, whereas primary biliary cirrhosis usually presents insidiously with liver test abnormalities and pruritus long before onset of jaundice. Interestingly, primary biliary cirrhosis can also be associated with keratoconjunctivitis sicca, and the histology of the involved salivary and lacrimal glands resembles that of primary biliary cirrhosis with intense inflammation and damage to small bile ducts, with rupture and granulomatous inflammation in the acute phase. This striking syndrome, several cases of which have been reported after short courses of thiabendazole, has not been reported with the other anthelmintic benzimidazoles, mebendazole and albendazole.</p></div></div></div><div id="Thiabendazole.PRODUCT_INFORMATION"><h2 id="_Thiabendazole_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Thiabendazole &#x02013; Mintezol&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Anthelmintic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=thiabendazole" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Thiabendazole.CHEMICAL_FORMULA_AND_STRUC"><h2 id="_Thiabendazole_CHEMICAL_FORMULA_AND_STRUC_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Thiabendazole.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548194/table/Thiabendazole.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Thiabendazole.Te_lrgtbl__"><table><thead><tr><th id="hd_h_Thiabendazole.Te_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Thiabendazole.Te_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Thiabendazole.Te_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Thiabendazole.Te_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Thiabendazole.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Thiabendazole</td><td headers="hd_h_Thiabendazole.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134975426" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">148-79-8</a></td><td headers="hd_h_Thiabendazole.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C10-H7-N3-S</td><td headers="hd_h_Thiabendazole.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134975426" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134975426" alt="image 134975426 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Thiabendazole.CITED_REFERENCE"><h2 id="_Thiabendazole_CITED_REFERENCE_">CITED REFERENCE</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Thiabendazole.REF.1">Roy MA, Nugent FW, Aretz HT. Micronodular cirrhosis after thiabendazole. <span><span class="ref-journal">Dig Dis Sci. </span>1989;<span class="ref-vol">34</span>:938–41.</span> [<a href="/pubmed/2721325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2721325</span></a>]</div></dd></dl></div><div id="Thiabendazole.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Thiabendazole_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 20 July 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Thiabendazole.REF.zimmerman.1999">Zimmerman HJ. Antihelminthics. Hepatic injury from antimicrobial agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 626-8.<div><i>(Expert review of hepatotoxicity of anthelmintics written in 1999; mentions that thiabendazole has been associated with at least 17 instances of cholestatic jaundice).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.keiser.2018">Keiser J, McCarthy J, Hotez P. Chemotherapy of helminth infections. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1001-9.<div><i>(Textbook of pharmacology and therapeutics; albendazole and mebendazole are discussed but not thiabendazole).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.hennekeuser.1969.582">Hennekeuser HH, Pabst K, Poeplau W, Gerok W. Thiabendazole for the treatment of trichinosis in humans. <span><span class="ref-journal">Tex Rep Biol Med. </span>1969;<span class="ref-vol">27</span> Suppl 2:582–96.</span> [<a href="/pubmed/5369623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5369623</span></a>]<div><i>(Among 23 patients with trichinosis [during an epidemic in Germany], treated with thiabendazole [50 mg/kg/day] for 10 days, one patient [4%] developed liver injury with ALT and AST elevations and biopsy showing hepatocellular necrosis and cholestasis; no further information given).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.bayles.1971.476">Bayles MAH. Chromomycosis: treatment with thiabendazole. <span><span class="ref-journal">Arch Dermatol. </span>1971;<span class="ref-vol">104</span>:476–85.</span> [<a href="/pubmed/5120175" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5120175</span></a>]<div><i>(Among 14 patients with chromomycosis treated with thiabendazole [25 mg/kg/day] long term, 5 developed toxic-allergic hepatitis arising after 1-18 months of therapy, 4 with jaundice, 1 died; rapid recurrence on restarting; few details given).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.jalota.1974.676">Jalota R, Freston JW. Severe intrahepatic cholestasis due to thiabendazole. <span><span class="ref-journal">Am J Trop Med Hyg. </span>1974;<span class="ref-vol">23</span>:676–8.</span> [<a href="/pubmed/4847042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4847042</span></a>]<div><i>(32 year old woman developed fever and rash a day after finishing 8 day course of thiabendazole for pinworms, with subsequent jaundice [bilirubin rising to 23 mg/dL, AST 123 U/L, Alk P 209 U/L]; liver biopsy showed intrahepatic cholestasis, but she died of hemorrhage, a complication of transhepatic cholangiogram).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.feregrino_goyos.1976.167">Feregrino Goyos M, Lifshitz Guinzberg A, Hern&#x000e1;ndez Berumen A, Ram&#x000ed;rez Degollado J, Cervantes LF. <span><span class="ref-journal">Prensa Med Mex. </span>1976;<span class="ref-vol">41</span>:167–71.</span> [Intrahepatic cholestasis by thiabendazole treated with phenobarbital] Spanish. [<a href="/pubmed/995842" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 995842</span></a>]</div></li><li><div class="bk_ref" id="Thiabendazole.REF.fink.1978.108">Fink AI, MacKay CJ, Cutler SS. Sicca complex and cholestatic jaundice in two members of a family caused by thiabendazole. <span><span class="ref-journal">Trans Am Ophthalmol Soc. </span>1978;<span class="ref-vol">76</span>:108–15.</span> [<a href="/pmc/articles/PMC1311616/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1311616</span></a>] [<a href="/pubmed/754367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 754367</span></a>]<div><i>(Mother and daughter developed sicca syndrome followed by jaundice after 5 members of family were given 2 doses of thiabendazole for pinworms; mother, aged 43, developed symptoms at 2 weeks with parotid enlargement, dry mouth and eyes, and jaundice 1 week later [peak bilirubin 15.7 mg/dL, Alk P 944 U/L, AST 200 U/L], resolving in 1 month; child, aged 17, had onset of symptoms in 1 week and jaundice in 2, with prolonged jaundice, pruritus and dry eyes, ultimately resolving).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.fink.1979.1892">Fink AI, MacKay CJ, Cutler SS. Sicca complex and cholangiostatic jaundice in two members of a family probably caused by thiabendazole. <span><span class="ref-journal">Ophthalmology. </span>1979;<span class="ref-vol">86</span>:1892–6.</span> [<a href="/pubmed/553260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 553260</span></a>]<div><i>(Same cases as described by the authors in Trans Am Ophthalmol Soc 1978).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.rex.1983.718">Rex D, Lumeng L, Eble J, Rex L. Intrahepatic cholestasis and sicca complex after thiabendazole. Report of a case and review of the literature. <span><span class="ref-journal">Gastroenterology. </span>1983;<span class="ref-vol">85</span>:718–21.</span> [<a href="/pubmed/6873616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6873616</span></a>]<div><i>(55 year old man developed jaundice 8 days after starting a 3 day course of thiabendazole for strongyloidiasis [bilirubin 30.6 rising to 40.5 mg/dL, AST 562 U/L, Alk P 820 U/L], and dry eyes, but normal salivary gland biopsy, liver biopsy showing intrahepatic cholestasis without duct loss, prolonged, severe course [confusion and edema], but ultimate recovery).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.manivel.1987.245">Manivel JC, Bloomer JR, Snover DC. Progressive bile duct injury after thiabendazole administration. <span><span class="ref-journal">Gastroenterology. </span>1987;<span class="ref-vol">93</span>:245–9.</span> [<a href="/pubmed/3297909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3297909</span></a>]<div><i>(27 year old man developed jaundice 2 weeks after finishing 1 week course of thiabendazole for suspected strongyloidiasis [peak bilirubin 24.5 mg/dL, ALT 328 U/L, Alk P 6280 U/L], liver biopsies showing duct injury and loss, followed by intractable pruritus and liver failure and liver transplant 3 years after onset).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.davidson.1988.620">Davidson RN, Weir WR, Kaye GL, McIntyre N. Intrahepatic cholestasis after thiabendazole. <span><span class="ref-journal">Trans R Soc Trop Med Hyg. </span>1988;<span class="ref-vol">82</span>:620.</span> [<a href="/pubmed/3256116" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3256116</span></a>]<div><i>(17 year old boy developed dry mouth 1 day after finishing 3 day course of thiabendazole for strongyloides infection, becoming jaundiced 2 weeks later [bilirubin rising to 23.8 mg/dL, ALT 102 U/L, Alk P 350 U/L], biopsy showed severe intrahepatic cholestasis, jaundice resolved in 6 and serum enzyme elevations in 12 months).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.roy.1989.938">Roy MA, Nugent FW, Aretz HT. Micronodular cirrhosis after thiabendazole. <span><span class="ref-journal">Dig Dis Sci. </span>1989;<span class="ref-vol">34</span>:938–41.</span> [<a href="/pubmed/2721325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2721325</span></a>]<div><i>(46 year old woman developed dry eyes and mouth 2 weeks after a 5 day course of thiabendazole for trichinosis, followed by jaundice and pruritus 1 week later [bilirubin 16.4 mg/dL, ALT 487 U/L], liver biopsy showed intrahepatic cholestasis and paucity of bile ducts, with prolonged jaundice and pruritus and variceal hemorrhage 2.5 years later: Case 1).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.bion.1995.762">Bion E, Pariente EA, Maitre F. Severe cholestasis and sicca syndrome after thiabendazole. <span><span class="ref-journal">J Hepatol. </span>1995;<span class="ref-vol">23</span>:762–3.</span> [<a href="/pubmed/8750181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8750181</span></a>]<div><i>(56 year old man developed severe dry mouth and eyes 2 weeks after a 3 day course of thiabendazole, followed 3 days later by jaundice [bilirubin rising to 27.2 mg/dL, ALT 5.5 times ULN, Alk P 8 times ULN, GGT 29 times ULN], liver biopsy showed intrahepatic cholestasis and salivary gland biopsy sialadenitis, slow recovery and persistent GGT elevation 6 years later).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.skandrani.1997.623">Skandrani K, Richardet JP, Duvoux C, Cherqui D, Zafrani ES, Dhumeaux D. <span><span class="ref-journal">Gastroenterol Clin Biol. </span>1997;<span class="ref-vol">21</span>:623–5.</span> [Hepatic transplantation for severe ductopenia related to ingestion of thiabendazole] French. [<a href="/pubmed/9587501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9587501</span></a>]<div><i>(26 year old man developed dry eyes and dry mouth 4 days after finishing a second course of thiabendazole [25 mg/kg for 3 days] for strongyloidiasis, with subsequent jaundice [bilirubin 18.3 mg/dL, ALT 2.5 times ULN, Alk P 1.5 times ULN], liver biopsy showed intrahepatic cholestasis and loss of bile ducts; subsequent persistent severe cholestasis evolving into cirrhosis; liver transplant 1.5 years after onset).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.eland.1998.1331">Eland IA, Kerkhof SC, Overbosch D, Wismans PJ, Stricker BH. <span><span class="ref-journal">Ned Tijdschr Geneeskd. </span>1998;<span class="ref-vol">142</span>:1331–4.</span> [Cholestatic hepatitis ascribed to the use of thiabendazole] Dutch. [<a href="/pubmed/9752041" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9752041</span></a>]<div><i>(Two women with cholestatic hepatitis arising 2-3 weeks after 2 day course of thiabendazole for strongyloidiasis, with slow and incomplete recovery).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF17">Drugs for parasitic infections. <span><span class="ref-journal">Treat Guidel Med Lett. </span>2013;<span class="ref-vol">11</span> Suppl:e1–31.</span><div><i>(Brief description of drugs for parasitic infections in adults and children as well as a table of their major side effects; thiabendazole is mentioned as a drug of choice and is not discussed).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.bisoffi.2011.e1254">Bisoffi Z, Buonfrate D, Angheben A, Boscolo M, Anselmi M, Marocco S, Monteiro G, et al.  Randomized clinical trial on ivermectin versus thiabendazole for the treatment of strongyloidiasis. <span><span class="ref-journal">PLoS Negl Trop Dis. </span>2011;<span class="ref-vol">5</span>:e1254. </span> [<a href="/pmc/articles/PMC3144183/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3144183</span></a>] [<a href="/pubmed/21814588" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21814588</span></a>]<div><i>(Controlled trial of thiabendazole [2 daily doses for 2 days] vs ivermectin [single dose] in 198 patients with Strongyloidiasis found similar efficacy, but fewer side effects with ivermectin; no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.groh.2012.s107">Groh M, Blanche P, Calmus Y, Guillevin L. Thiabendazole-induced acute liver failure requiring transplantation and subsequent diagnosis of polyarteritis nodosa. <span><span class="ref-journal">Clin Exp Rheumatol. </span>2012;<span class="ref-vol">30</span>(1) Suppl 70:S107–9.</span> [<a href="/pubmed/22640653" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22640653</span></a>]<div><i>(33 year old man with chronic hypereosinophilia developed severe liver injury after experimental therapy with thiabendazole which resulted in vanishing bile duct syndrome, hepatic failure and liver transplantation; few details given).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, only one of which was attributed to an anthelmintic, mebendazole; none were attributed to thiabendazole).</i></div></div></li><li><div class="bk_ref" id="Thiabendazole.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 409 [46%] were attributed to antimicrobial agents, but none to anthelmintics or to thiabendazole).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548194</span><span class="label">PMID: <a href="/pubmed/31643521" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643521</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Theophylline/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/ThiazideDiuretics/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548194&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548194/?report=reader">PubReader</a></li><li><a href="/books/NBK548194/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548194" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548194" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Thiabendazole. [Updated 2020 Jul 20].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548194/pdf/Bookshelf_NBK548194.pdf">PDF version of this page</a> (109K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Thiabendazole/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Thiabendazole: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Thiabendazole" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Thiabendazole: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4864782" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4864782" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4864782" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17536622" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Comparison of various anthelmintic therapies for the treatment of Trypanoxyuris microon infection in owl monkeys (Aotus nancymae).</a><span class="source">[Comp Med. 2007]</span><div class="brieflinkpop offscreen_noflow">Comparison of various anthelmintic therapies for the treatment of Trypanoxyuris microon infection in owl monkeys (Aotus nancymae).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bentzel DE, Bacon DJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Comp Med. 2007 Apr; 57(2):206-9. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28825538" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Development and Validation of a Fast Stability-Indicating Ion-Paired Reversed-Phase HPLC Method for the Assay of Thiabendazole and Estimation of Its Related Compounds.</a><span class="source">[J AOAC Int. 2017]</span><div class="brieflinkpop offscreen_noflow">Development and Validation of a Fast Stability-Indicating Ion-Paired Reversed-Phase HPLC Method for the Assay of Thiabendazole and Estimation of Its Related Compounds.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zhang P, Tian J, Rustum A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J AOAC Int. 2017 Jan 1; 100(1):74-81. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/9752041" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[Cholestatic hepatitis ascribed to the use of thiabendazole].</a><span class="source">[Ned Tijdschr Geneeskd. 1998]</span><div class="brieflinkpop offscreen_noflow">[Cholestatic hepatitis ascribed to the use of thiabendazole].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Eland IA, Kerkhof SC, Overbosch D, Wismans PJ, Stricker BH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ned Tijdschr Geneeskd. 1998 Jun 6; 142(23):1331-4. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26778150" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.</a><span class="source">[Cochrane Database Syst Rev. 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Henriquez-Camacho C, Gotuzzo E, Echevarria J, White AC Jr, Terashima A, Samalvides F, Pérez-Molina JA, Plana MN. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cochrane Database Syst Rev. 2016 Jan 18; (1):CD007745. Epub 2016 Jan 18.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17940124" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection.</a><span class="source">[Ann Pharmacother. 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Segarra-Newnham M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Pharmacother. 2007 Dec; 41(12):1992-2001. Epub 2007 Oct 16.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643521" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643521" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60469540b1d385378a612166">Thiabendazole - LiverTox</a><div class="ralinkpop offscreen_noflow">Thiabendazole - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T16:21:05-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal101&amp;ncbi_phid=CE88C0AD046909C100000000010B004A&amp;ncbi_session=CE88C0AD046953F1_0267SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548194%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548194&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548194/&amp;ncbi_pagename=Thiabendazole - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88C0AD046953F1_0267SID /projects/books/PBooks@9.2 portal101 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>